BACKGROUND Prior research has suggested that the prevalence and outcomes of
pulmonary arterial hypertension (PAH) may vary by race or ethnicity. However, these studies …

Rationale: Limited information is available on racial/ethnic differences in pulmonary arterial
hypertension (PAH). Objectives: Determine effects of race/ethnicity and ancestry on mortality …

This study explores the racial and ethnic differences in presentation, severity, and treatment
of patients with pulmonary arterial hypertension (PAH) in a large multicenter registry. African …

Rationale: There is a noticeable underrepresentation of minorities in clinical trials and
registries in pulmonary arterial hypertension (PAH). Prior studies evaluating the association …

Rationale: Lower socioeconomic status (SES) confers a heightened risk of common
cardiovascular and pulmonary diseases and increased mortality. The association of SES …

BACKGROUND Pulmonary arterial hypertension (PAH) is a rare, severe disease
characterized by worsening right-sided heart failure, decreasing functional status, and poor …

In the past decade and a half, the introduction of new therapeutic agents has revolutionized
the management of pulmonary arterial hypertension (PAH). These new treatment options …

Purpose Pulmonary arterial hypertension (PAH) is progressive and associated with early
demise. Risk assessment tools help predict prognosis and optimize disease management. A …

Background In recent years, the population of patients with pulmonary arterial hypertension
(PAH) has changed dramatically, including more advanced age at diagnosis. We …

Background—Factors that determine survival in pulmonary arterial hypertension (PAH) drive
clinical management. A quantitative survival prediction tool has not been established for …